Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 333.58M | 310.20M | 249.43M | 143.74M | 26.52M | 30.11M |
Gross Profit | 330.26M | 307.47M | 248.39M | 143.28M | -46.71M | -44.70M |
EBITDA | -44.60M | -70.46M | -51.65M | -38.35M | -166.72M | ― |
Net Income | -21.63M | -51.09M | -55.29M | -41.22M | -131.52M | -74.09M |
Balance Sheet | ||||||
Total Assets | 1.03B | 1.01B | 597.00M | 435.52M | 301.77M | 197.19M |
Cash, Cash Equivalents and Short-Term Investments | 837.03M | 820.38M | 442.63M | 332.54M | 237.89M | 129.72M |
Total Debt | 42.47M | 432.72M | 84.03M | 69.30M | 63.84M | 63.89M |
Total Liabilities | 649.53M | 648.79M | 228.16M | 156.76M | 130.23M | 141.85M |
Stockholders Equity | 378.48M | 360.72M | 368.84M | 278.76M | 171.55M | 55.35M |
Cash Flow | ||||||
Free Cash Flow | 26.04M | 20.89M | -2.48M | -33.47M | -130.76M | -63.65M |
Operating Cash Flow | 31.08M | 26.06M | 2.94M | -31.27M | -129.75M | -60.57M |
Investing Cash Flow | -345.00M | -355.13M | -5.42M | 233.00K | -495.00K | 467.00K |
Financing Cash Flow | -49.58M | 343.88M | 34.35M | 138.23M | 276.25M | 115.94M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
58 Neutral | $1.98B | ― | -16.57% | ― | ― | ― | |
53 Neutral | $1.87B | ― | -31.34% | ― | -54.85% | -79.25% | |
51 Neutral | $1.31B | ― | -422.66% | ― | 49.29% | 44.52% | |
50 Neutral | $1.56B | ― | -5.78% | ― | 25.50% | 64.63% | |
46 Neutral | C$190.36M | -4.25 | -8.56% | 3.09% | 13.53% | -1.76% | |
43 Neutral | $1.89B | ― | -23.34% | ― | ― | -14.19% | |
39 Underperform | $1.44B | ― | -39.49% | ― | ― | -20.03% |
On May 15, 2025, Immunocore Holdings plc held its Annual General Meeting where shareholders approved all thirteen resolutions presented. These included the re-appointment of directors, approval of executive compensation, and authorization for the company to make political donations and allot shares. The successful passage of these resolutions indicates strong shareholder support for the company’s current management and strategic direction, potentially reinforcing its operational stability and market confidence.
The most recent analyst rating on (IMCR) stock is a Hold with a $35.00 price target. To see the full list of analyst forecasts on Immunocore Holdings stock, see the IMCR Stock Forecast page.